Viatris has acquired Pacira BioSciences for $1.65 billion to enhance its non-opioid pain therapy portfolio. This strategic move aligns with Viatris' goal to expand its offerings in the pain management market as it approaches the approval of its internal non-opioid program.
With an internal non-opioid program nearing approval, Viatris is picking up Pacira BioSciences for a broader pain portfolio and the associated commercial infrastructure.
Original title: “Viatris inks $1.65B Pacira buyout to build non-opioid pain therapy business”